<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381703</url>
  </required_header>
  <id_info>
    <org_study_id>YH12852-103(I)</org_study_id>
    <nct_id>NCT03381703</nct_id>
  </id_info>
  <brief_title>Investigation of the Absorption, Metabolism, and Excretion and the Absolute Bioavailability of YH12852</brief_title>
  <official_title>A Phase I Study to Investigate the Absorption, Metabolism, and Excretion and the Absolute Bioavailability of YH12852 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the absorption, metabolism, and excretion and the absolute
      bioavailability of YH12852 in healthy male subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 : Investigate the absorption metabolism, and excretion of YH12852 after single oral
      administration of YH12852 and 14C-labeled YH12852.

      Part 2

      : Investigate the absolute bioavailability of YH12852 after single oral administration of
      YH12852 followed by a single i.v. administration of 14C-labeled YH12852.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Actual">March 29, 2017</completion_date>
  <primary_completion_date type="Actual">March 29, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total radioactivity</measure>
    <time_frame>0 - 288 hours (post-dose)</time_frame>
    <description>Total radioactivity recovered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of YH12852</measure>
    <time_frame>0(pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288 hours (post-dose)</time_frame>
    <description>Peak concentration of YH12852</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of YH12852</measure>
    <time_frame>0(pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288 hours (post-dose)</time_frame>
    <description>Area under the concentration-time curve from time 0 to the last measurable time of YH12852</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fpo of YH12852</measure>
    <time_frame>0(pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288 hours (post-dose)</time_frame>
    <description>Oral bioavailability of YH12852</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aef of YH12852</measure>
    <time_frame>0 - 288 hours (post-dose)</time_frame>
    <description>Amount excreted in feces of YH12852</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aeu of YH12852</measure>
    <time_frame>0 - 288 hours (post-dose)</time_frame>
    <description>Amount excreted in urine of YH12852</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigate the absorption, metabolism, and excretion of YH12852</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigate the absolute bioavailability of YH12852</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852</intervention_name>
    <description>YH12852 administration</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-labeled YH12852</intervention_name>
    <description>14C-labeled YH12852 administration</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who agreed to voluntarily participate in this study and comply with all the
             study requirements by signing informed consent form after being informed of the nature
             of this study and understanding all aspects of this study

          -  Healthy adult, 19 - 55 of age (inclusive)

          -  Subjects weighing over 55 kg (inclusive) with BMI between 18 and 25 (inclusive) at
             screening visit

          -  Subjects with no clinically significant abnormal findings as determined by physical
             examination, ECG, medical history, or clinical laboratory test results

        Exclusion Criteria:

          -  History of clinically significant gastrointestinal, hepatic, renal, respiratory,
             cardiovascular, metabolic, immunological or hormonal disorder

          -  Surgery of the gastrointestinal tract that could interfere with kinetics of the study
             drug

          -  History of (or suspected at screening visit) disease listed below Myocardial
             infarction Cerebral infarction/Stroke Arrythmia that need medical treatment Unstable
             angina Pulmonary hypertension

          -  Subjects who are positive for Hepatitis B, Hepatitis C, and HIV

          -  History of relevant allergy/hypersensitivity

          -  Subjects who took prescribed medications within 14 days or over-the-counter (OTC)
             medications within 7 days prior to the first dose of the study drug

          -  Subjects who have been consuming over 21 unit(1 unit = 10 g of alcohol) per week of
             alcohol prior to the study initiation or who is not able to stop consuming alcohol
             throughout the hospitalization period

          -  Subjects who consumed products listed below within 2 days prior to the first dose of
             the study drug or who is not able to stop consuming products listed below until the
             last site visit Foods and/or beverages containing grapefruit Products containing
             caffeine (Coffee, tea, chocolate, caffeine-containing soft drinks)

          -  Subject who is not willing to use contraception throughout the study

          -  Subjects who have smoked over 10 cigarettes until 3 months prior to the study
             initiation or who is not able to stop smoking throughout the hospitalization period

          -  Subjects who have donated whole blood within 2 months or blood component within 1
             month or received blood transfusion within 1 month of participating in this study

          -  Administration of any investigational products within 3 months from the first dose of
             the study drug

          -  Subject who's serum prolactin is over 3-fold higher than the upper limit of normal
             range

          -  Subject who judged not eligible for study participation by investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Lee, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2017</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Accelerated Mass Spectrometry</keyword>
  <keyword>Microtracer</keyword>
  <keyword>Microdose</keyword>
  <keyword>hAME</keyword>
  <keyword>Absolute bioavailability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

